PAVmed Inc. · NASDAQ:PAVM
PAVmed — Q3 2026 Earnings Presentation
12 slides from PAVmed's earnings presentation, Nov 13, 2026
Slide 1: Q3 2026 Business Update
Nasdaq: PAVM Q3 2026 Business Update November 13, 2026 LISHAN AKLOG, MD Chairman & CEO DENNIS MCGRATH President & CFO
Slide 2: Disclaimer
Disclaimer ▪ This presentation may contain certain forward-looking statements related to PAVmed Inc. or Lucid Diagnostics Inc. (the “Companies”) that involve risks and uncertainties. ▪ Actual results and events may differ significantly from results and events discussed in forward- looking statements
Slide 3: Lishan Aklog, M.D., Chairman & CEO
Nasdaq: PAVM Lishan Aklog, M.D. Chairman & CEO
Slide 4: PAVmed Corporate Structure
PAVmed Corporate Structure Nasdaq: PAVM D IAGNOSTIC S D I G I T A L H E A L T H Medical Device Portfolio Nasdaq: LUCD Privately Held Privately Held Early Detection of Esophageal Precancer Digital Cancer Care Platform & Smart Vascular Access Incubator for MedTech Technologies, including PortIO Port a
Slide 5: Recent Highlights
Recent Highlights Veris Health ▪ Commercial phase of OSU strategic engagement accelerating, with monthly enrollment growing throughout the quarter ▪ Clinical rollout live across most departments, with remaining departments in implementation ▪ Implantable physiological monitor design freeze achieved
Slide 6: Recent Highlights
Recent Highlights PortIO ▪ Initial FDA meeting held in October ▪ In-person FDA pre-submission meeting scheduled for January 2027 Octeris ▪ Next-generation probe ready for clinical testing ▪ Initial FDA pre-submission package targeted for November ▪ UNC clinical validation study enrollment expected t
Slide 7: Q3 2026 Financial Update
Nasdaq: PAVM Q3 2026 Financial Update
Slide 8: Balance Sheet
Balance Sheet ($ in thousands) 3Q26 2Q26 Change Assets Cash and restricted cash $8,935 $3,784 $5,151 Equity Method Investments (Lucid) $23,508 $33,494 $(9,986) All other Assets $2,763 $2,936 $(173) Liabilities Accounts Payable $1,037 $1,056 $(19) Senior Secured Convertible Notes* $14,200* $15,100 $(
Slide 9: P&L 3Q26 3Q25
P&L ($ in thousands) 3Q26 3Q25 Change 3Q26 - YTD 3Q25 - YTD Change Revenue + Management Fee Income $3,191 $3,155 $36 $9,546 $9,469 $77 Operating Expenses $6,768 $4,849 $1,919 $21,879 $15,022 $6,857 Net Income (Loss) $(13,035) $(6,011) $(7,024) $(20,696) $288 $(20,984) EBITDA $(11,906) $(5,363) $(6,5
Slide 10: Non-GAAP Operating Expense
Non-GAAP Operating Expense 8,000 7,000 6,253 6,119 6,000 5,904 5,642 5,000 4,392 4,000 3,000 2,000 1,000 0 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Cost of Revenue Sales and Marketing General & Admin R&D Total To supplement our unaudited financial results presented in accordance with U.S. generally a
Slide 11: Q&A
XK PAVmed Nasdaq: PAVM 2 a: Q&A
Slide 12: Closing Remarks
Nasdaq: PAVM Closing Remarks